Research Topics
| J B WongSummaryAffiliation: Rhode Island Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the futureJohn B Wong
Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
Hepatology 36:252-4. 2002- Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritisJohn B Wong
Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
Am J Med 113:400-8. 2002..To estimate the cost-effectiveness of infliximab plus methotrexate for active, refractory rheumatoid arthritis... 
Estimating future hepatitis C morbidity, mortality, and costs in the United StatesJ B Wong
Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass, USA
Am J Public Health 90:1562-9. 2000..This study estimated future morbidity, mortality, and costs resulting from hepatitis C virus (HCV)...- Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysisJ B Wong
New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111, USA
Ann Intern Med 133:665-75. 2000..Not all patients with histologically mild chronic hepatitis C progress to cirrhosis... - Long-term morbidity, mortality, and economics of rheumatoid arthritisJ B Wong
New England Medical Center, Boston, MA 02111, USA
Arthritis Rheum 44:2746-9. 2001..To estimate the morbidity, mortality, and lifetime costs of care for rheumatoid arthritis (RA)... - Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costsJ B Wong
Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
JAMA 280:2088-93. 1998..Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response... - Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis CU Siebert
Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Gut 52:425-32. 2003..CONCLUSIONS: Peginterferon alpha-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C... - Patient-specific decisions about hormone replacement therapy in postmenopausal womenN F Col
Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Mass 02111, USA
JAMA 277:1140-7. 1997..To examine the effect of hormone replacement therapy on life expectancy in postmenopausal women with different risk profiles for heart disease, breast cancer, and hip fracture... - Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysisS J Cheng
New England Medical Center, Tufts University School of Medicine, 750 Washington St, PO Box 302, Boston, MA 02111, USA
Transplantation 72:861-8. 2001..CONCLUSIONS: Living-donor liver transplantation should confer a substantial survival advantage for patients with compensated cirrhosis and non-resectable early stage hepatocellular carcinoma... - Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysisE M Balk
Evidence-based Practice Center, Division of Clinical Care Research, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA
J Gen Intern Med 16:701-11. 2001..Newer, expensive antibiotics are of limited value. Additional testing is not cost-effective. Further studies are needed to find an accurate,low-cost diagnostic test for acute bacterial sinusitis... - Cost-effectiveness of anti-tumor necrosis factor agentsJ B Wong
Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
Clin Exp Rheumatol 22:S65-70. 2004..This paper reviews the disease burden of rheumatoid arthritis, costs of drug therapy, costs of rheumatoid arthritis and the economics and cost-effectiveness of anti-tumor necrosis factor antibody agents... - Using observational data to estimate prognosis: an example using a coronary artery disease registryE R DeLong
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Duke University, Department of Medicine, Biometry Division, Community and Family Medicine, 2400 Pratt Street, Durham, NC 27705, USA
Stat Med 20:2505-32. 2001..This paper discusses these issues and suggests strategies to deal with them. A proposed methodology is developed, applied and evaluated on a large observational database that has long-term follow-up on nearly 10 000 patients... - Fitting nutrition into the medical model: the role of decision analytic cost-effectiveness techniquesE M Ross
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, USA
Eur J Clin Nutr 53:S25-8. 1999.... - Early infection in bone marrow transplantation: quantitative study of clinical factors that affect riskE A Engels
Department of Medicine, Tupper Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
Clin Infect Dis 28:256-66. 1999..Ciprofloxacin prophylaxis and particularly intravenous antibiotic therapy provide substantial protection at low neutrophil counts. These results can be used to model management strategies for transplant recipients... - The economics of hepatitis C virusBhavesh B Shah
Division of Clinical Decision Making, Informatics, and Telemedicine, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street #302, Boston, MA 02111, USA
Clin Liver Dis 10:717-34. 2006..The global economic burden of this disease has yet to be fully realized. In this article the authors discuss the economic burden of hepatitis C, the economics of therapy, and the economics of its prevention and screening... - Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis CJohn B Wong
Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
Am J Gastroenterol 98:2354-62. 2003..Decisions regarding continuation of antiviral treatment should also consider the variability in the accuracy of quantitative viral assays as well as patient preferences and other potential benefits of the same treatments... - Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CGary L Davis
Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
Hepatology 38:645-52. 2003..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases... - Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference caseAndreas Maetzel
Division of Clinical Decision Making and Health Care Research, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
J Rheumatol 30:891-6. 2003..We provide the rationale for each element and discuss how each element has been addressed in published economic evaluations of DMARD... - Intermittent claudication: cost-effectiveness of revascularization versus exercise therapySybolt O de Vries
Department of Health Sciences, University of Groningen, The Netherlands
Radiology 222:25-36. 2002..Angioplasty performed whenever feasible was more effective than was exercise alone, and the cost-effectiveness ratio was within the generally accepted range... - The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UKMarco Barbieri
Universitat Pompeu Fabra, Barcelona, Spain
Pharmacoeconomics 23:607-18. 2005.... - Strategies for managing anemia in hepatitis C patients undergoing antiviral therapyJohn G McHutchison
Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
Am J Gastroenterol 102:880-9. 2007..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications... - Economics of chronic hepatitis B and hepatitis CArathi Rajendra
Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, NEMC 302, Boston, MA 02111, USA
J Hepatol 47:608-17. 2007..This review should help clinicians understand economic issues regarding new drugs and answer questions about whether the clinical benefit provided by a medication justifies its expense... - Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapiesJohn B Wong
Division of Clinical Decision Making, Department of Medicine, Tufts University School of Medicine, Tufts New England Medical Center, Tupper Research Institute, Boston, Massachusetts 02111, USA
Pharmacoeconomics 24:661-72. 2006.... - Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysisYoav Golan
Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
Ann Intern Med 143:857-69. 2005..Mortality from invasive candidiasis is high. Low culture sensitivity and treatment delay contribute to increased mortality, but nonselective early therapy may result in excess costs and drug resistance... - DEALE-ing with lung cancer and heart failureManu Sondhi
Department of Medicine, Division of Clinical Desicion Making, Tufts-New England Medical Center, Boston, Massachusetts, USA
Med Decis Making 25:82-94. 2005 - Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysisManish G Amin
Division of Gastroenterology and Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
Liver Transpl 10:1468-75. 2004..At less advanced MELD scores, the survival benefit depends on the risk of PGF associated with the ECD organ... - All dysuria is local. A cost-effectiveness model for designing site-specific management algorithmsMichael B Rothberg
Division of Clinical Decision Making, Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 01199, USA
J Gen Intern Med 19:433-43. 2004..To determine the cost-effectiveness of management strategies for dysuria in different office settings... - Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990Murray Krahn
Toronto General Hospital, ES9 408, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
Med Decis Making 24:20-9. 2004..To develop a natural history model for chronic hepatitis C virus (HCV) infection to determine allocation of compensatory funds to Canadians who acquired HCV through the blood supply from 1986 through 1990... - Estimating hip fracture morbidity, mortality and costsR Scott Braithwaite
Section of Decision Sciences and Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
J Am Geriatr Soc 51:364-70. 2003..To estimate lifetime morbidity, mortality, and costs from hip fracture incorporating the effect of deficits in activities of daily living... - Simulation of hepatitis C based on a mandatory reporting systemMarkus Sagmeister
Division of Gastroenterology and Hepatology, University Hospital, , Switzerland
Eur J Gastroenterol Hepatol 14:25-34. 2002..CONCLUSIONS : The incidence of HCV-related cirrhosis is predicted to decrease after 2005-2010, while disease burden and costs due to complications are estimated to continue to increase until 2015-2020... 
Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harmsCraig E Gordon
Division of Nephrology, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA 02111, USA
Am J Kidney Dis 51:263-77. 2008..We determined the efficacy and harms of interferon (IFN) and pegylated IFN (PEG-IFN) treatment of hemodialysis patients with chronic HCV infection and identified factors associated with these outcomes...